Highview Capital Management LLC DE Purchases 85 Shares of Eli Lilly and Company $LLY

Highview Capital Management LLC DE raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% in the second quarter, HoldingsChannel reports. The fund owned 5,793 shares of the company’s stock after acquiring an additional 85 shares during the period. Eli Lilly and Company accounts for approximately 1.7% of Highview Capital Management LLC DE’s investment portfolio, making the stock its 15th largest holding. Highview Capital Management LLC DE’s holdings in Eli Lilly and Company were worth $4,516,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in LLY. Bridger Management LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $5,696,000. Perennial Investment Advisors LLC raised its position in Eli Lilly and Company by 3.1% in the 2nd quarter. Perennial Investment Advisors LLC now owns 1,868 shares of the company’s stock valued at $1,456,000 after buying an additional 57 shares during the last quarter. PFG Private Wealth Management LLC increased its position in shares of Eli Lilly and Company by 5.3% during the second quarter. PFG Private Wealth Management LLC now owns 457 shares of the company’s stock valued at $356,000 after acquiring an additional 23 shares during the last quarter. Semus Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 9.0% in the 2nd quarter. Semus Wealth Partners LLC now owns 4,003 shares of the company’s stock worth $3,120,000 after purchasing an additional 332 shares during the period. Finally, Bedell Frazier Investment Counselling LLC raised its stake in Eli Lilly and Company by 126.8% in the 2nd quarter. Bedell Frazier Investment Counselling LLC now owns 9,641 shares of the company’s stock valued at $7,515,000 after acquiring an additional 5,390 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,030.49 on Wednesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,040.72. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $974.21 billion, a P/E ratio of 67.35, a P/E/G ratio of 1.21 and a beta of 0.43. The company’s 50-day simple moving average is $838.20 and its two-hundred day simple moving average is $782.36.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the firm earned $1.18 earnings per share. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LLY. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday. UBS Group raised their price target on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Daiwa Capital Markets upped their price objective on Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,020.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.